Outer membrane vesicles (OMV) production of Neisseria meningitidis serogroup B in batch process

Vaccine

Volumn 30, Issue 42, 2012, Pages 6064-6069

  Santos, Sílvia ^a   de Arauz, Luciana Juncioni ^b   Baruque Ramos, Júlia ^c   Lebrun, Ivo ^d   Carneiro, Sylvia Mendes ^d   Barreto, Sandra Alves ^d   Schenkman, Rocilda Perazzini Furtado ^d  

^a Faculdade Adventista da Bahia   (Brazil)

^b INSTITUTO ADOLFO LUTZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO BUTANTAN   (Brazil)

Author keywords

Bioreactor systems; Kinetics; Neisseria meningitidis; Outer membrane vesicles; Vaccine

Indexed keywords

AMINO ACID; BACTERIAL VACCINE; GLYCEROL; LACTIC ACID;

AMINO ACID BLOOD LEVEL; ARTICLE; BATCH PROCESS; BIOREACTOR; CELL GROWTH; CELL VACUOLE; LACTATE BLOOD LEVEL; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; VIRUS CULTURE;

AMINO ACIDS; BACTERIAL OUTER MEMBRANE PROTEINS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; CULTURE MEDIA; GLYCEROL; IRON-REGULATORY PROTEINS; LACTIC ACID; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SECRETORY VESICLES;

EID: 84865553666     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.052     Document Type: Article

References (42)

1. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricó B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103(29):10834-10839.
2. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10(2):112-124.
3. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24(22):4692-4700.
4. Pollard A.J., Moxon E.R. The meningococcus tamed?. Arch Dis Child 2002, 87(1):13-17.
5. Wang Q., Shao Z., Wang X., Gao Y., Li M., Xu L., et al. Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serougroup A and C strains. Infect Immun 2010, 78(9):3883-3888.
6. Holst J., Martin D., Arnold R., Huergo C.C., Oster P., O'Hallahan J., et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(Suppl. 2):B3-B12.
7. Borrow R., Aaberge I.S., Santos G.F., Eudey T.L., Oster P., Glennie A., et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian Menbvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005, 12(8):970-976.
8. Franzoso S., Mazzon C., Sztukowska M., Cecchini P., Kasic T., Capecchi B., et al. Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J Leukoc Biol 2008, 83(5):1100-1110.
9. Yero D., Pajón R., Pérez Y., Fariñas M., Cobas K., Diaz D., et al. Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. Vaccine 2007, 25(28):5175-5188.
10. Van de Waterbeemd B., Streefland M., van der Ley P., Zomer B., van Dijken H., Martens D., et al. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 2010, 28(30):4810-4816.
11. Frasch C.E. Meningococcal vaccines: past, present and future. Meningococcal disease 1995, 245-283. John Wiley & Sons, Chichester, UK. K. Cartwright (Ed.).
12. Rosenqvist E., Høiby E.A., Wedege E., Kusecek B., Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 1993, 167(5):1065-1073.
13. Sacchi C.T., Gorla M.C., de Lemos A.P., Brandileone M.C. Considerations on the use of Neisseria meningitidis class 5 proteins as meningococcal BC vaccine components. Vaccine 1995, 13(1):112-118.
14. Knuf M., Kowalzik F., Kieninger D. Comparative effects of carrier proteins on vaccine-induced immune response. Vaccine 2011, 29(31):4881-4890.
15. Joshi V.S., Bajaj I.B., Survase S.A., Singhal R.S., Kennedy J.F. Meningococcal polysaccharide vaccines: a review. Carbohydr Polym 2009, 75(4):553-565.
16. Baruque-Ramos J., Hiss H., Converti A., Gonçalves V.M., Raw I. Accumulation of organic acids in cultivations of Neisseria meningitidis C. J Ind Microbiol Biotechnol 2006, 33(10):869-877.
17. Paz M.F., Baruque-Ramos J., Hiss H., Leal M.B.B., Vicentin M.A., Raw I. Polysaccharide production in batch process of Neisseria meningitidis serogroup C comparing Frantz, modified Frantz and Catlin 6 media. Braz J Microbiol 2003, 34:27-32.
18. van de Waterbeemd B., Streefland M., van Keulen L., van den Ijssel J., de Haan A., Eppink M.H., et al. Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine 2012, 30(24):3683-3690.
19. Corrêa AP. Formulation study of C anti-meningococcal polysaccharide vaccines, conjugated to B outer membrane vesicles of Neisseria meningitidis. Dissertation. São Paulo (SP): University of São Paulo; 2002.
20. Fukasawa LO. Development of conjugated serogroup B/C anti-meningococcal vaccine. Thesis. São Paulo (SP): University of São Paulo; 2004.
21. Byers H.L., Campbell J., van Ulsen P., Tommassen J., Ward M.A., Schultz-Knappe P., et al. Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring. J Proteomics 2009, 73(2):231-239.
22. Fukasawa L.O., Schenkman R.P., Perciani C.T., Carneiro S.M., Dias W.O., Tanizaki M.M. Optimization of the conjugation method for a serogroup B/C meningococcal vaccine. Biotechnol Appl Biochem 2006, 45(3):141-146.
23. Holmes J.D., Martin D., Ramsay C., Ypma E., Oster P. Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. Epidemiol Infect 2008, 136(6):790-799.
24. Gotschlich E.C., Liu T.Y., Artenstein M.D. Human immunity to the meningococcus: III. Preparation and immunochemical properties of the series A series B and series C meningococcal polysaccharides. J Exp Med 1969, 129:1349-1365.
25. Santos S., Baruque-Ramos J., Tanizaki M.M., Lebrun I., Schenkman R.P.F. Production of outer membrane vesicles (OMV) in batch cultivations of Neisseria meningitidis serogroup B. Braz J Microbiol 2006, 37(4):488-493.
26. American Oil Chemistry Society Glycerol.Method Ea 6-51 Official Methods and Recommended Practices of the American Oil Chemistry Society 1987, p. 6-51.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.H. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
28. Sambrook J., Fritsch E.F., Maniats T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Lab Press, New York. 2nd ed.
29. Brandileone M.C., Zanella R.C., Vieira V.S., Sacchi C.T., Milagres L.G., Frasch C.E. Induction of iron regulated proteins during normal growth of Neisseria meningitidis in a chemically defined medium. Rev Inst Med Trop Sao Paulo 1994, 36(4):301-310.
30. Devoe I.W., Gilchrist J.E. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 1973, 138(5):1156-1167.
31. Baart G.J., Zomer B., de Haan A., van de Pol L.A., Beuvery E.C., Tramper J., et al. Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol 2007, 8(7):R136.
32. Fu J., Bailey J., King J.J., Parker C.B., Robinett R.S., Kolodin D.G., et al. Recent advances in the large scale fermentation of Neisseria meningitidis group B for the production of an outer membrane protein complex. Biotechnology 1995, 13(2):170-174.
33. Baart G.J., de Jong G., Philippi M., vann't Riet K., van der Pol L.A., Beuvery E.C., et al. Scale-up for bulk production of vaccine against meningococcal disease. Vaccine 2007, 25(34):6399-6408.
34. Baart G.J., Willemsen M., Khatami E., de Haan A., Zomer B., Beuvery E.C., et al. Modeling Neisseria meningitidis B metabolism at different specific growth rates. Biotechnol Bioeng 2008, 101(5):1022-1035.
35. Luedeking R., Piret E.L. A kinetic study of the latic acid fermentation. Batch process at controlled pH. Batch process at controlled pH. J Bioch Microb Techn Eng 1959, 1(4):393-412.
36. Hiss H. Cinética de processos fermentativos. Engenharia Bioquímica - Biotecnologia Industrial 2001, Edgard Blücher, São Paulo. W. Schmidell, U.A. Lima, E. Aquarone, W. Borzani (Eds.).
37. Kahaner D., Moler C., Nash S. Numerical methods and software: computer methods for mathematical computations 1989, Englewood Cliffs, Prentice Hall.
38. Smith H., Yates E.A., Cole J.A., Parsons N.J. Lactate stimulation of gonococcal metabolism in media containing glucose: mechanism, impact on pathogenicity, and wider implications for other pathogens. Infect Immun 2001, 69(11):6565-6572.
39. Leighton M.P., Kelly D.J., Williamson M.P., An Shaw J.G. NMR and enzyme study of the carbon metabolism of Neisseria meningitidis. Microbiology 2001, 147:1473-1482.
40. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000, 287(5459):1809-1815.
41. Pollard A.J., Frasch C. Development of natural immunity of Neisseria meningitidis. Vaccine 2001, 19(11-12):1327-1346.
42. Capecchi B., Adu-Bobie J., Di Marcello F., Ciucchi L., Masignani V., Taddei A., et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55(3):687-698.